Reserpine
Overview
Ethosuximide is antiepileptic agent. It was introduced in 1960 as the third of three marketed succinimides. its origin is in the cyclic ureide structure. It has a considerable efficasy against pentylenetetrazol seizures and was introduced as a 'pure petit mal' drug. its popularity continues, based on its safety and efficasy. its role as the first choice anti-absence drug remains undiminished, in part because of the idiosyncratic hepatotoxicity of the alternative drug, valproic acid. Ethosuximide is administered orally.
Primary Characterstics
It is of Synthetic origin. . The Molecular Weight of Reserpine is 608.70.
Its pKa is 6.6.
Indications
Back to top
Pharmacokinetics
Oral absorption of Ethosuximide is found to be 97% ±2. Volume of distribution is found to be 0.7 l/kg and plasma protien binding is negligible. Presystemic metabolism is noted to be 0.00255% ±0.00155 and metabolism is reported hepatic. Renal Excretion accounts for 17-38% and plasma half life is 53-56 hr.
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Reserpine's dosage details are as follows:
Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
0.1 to 1 mg | 0.55 (0.55) | 24 hourly | PO | |
Paedriatic Dosage (20kg)
|
No data regarding the Paedriatic dosage details of Reserpine is available. |
Neonatal Dosage (3kg)
|
No data regarding the neonatal dosage details of Reserpine is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Caps, Syrup
Store in a well closed container, Below 30°C.
Back to top
Interference in Pathology
- Urinanalysis
- Liver Function Test (LFT)
Back to top
Brands / Trade Names of
Reserpine
Back to top
Previous Drug Generic - Next Drug Generic